Growth Metrics

Biogen (BIIB) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Biogen (BIIB) over the last 17 years, with Q4 2025 value amounting to -$48.9 million.

  • Biogen's Net Income towards Common Stockholders fell 11833.52% to -$48.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.3 billion, marking a year-over-year decrease of 2078.79%. This contributed to the annual value of $1.3 billion for FY2025, which is 2078.79% down from last year.
  • According to the latest figures from Q4 2025, Biogen's Net Income towards Common Stockholders is -$48.9 million, which was down 11833.52% from $466.5 million recorded in Q3 2025.
  • Over the past 5 years, Biogen's Net Income towards Common Stockholders peaked at $1.1 billion during Q3 2022, and registered a low of -$134.8 million during Q3 2021.
  • Its 5-year average for Net Income towards Common Stockholders is $392.4 million, with a median of $395.3 million in 2023.
  • Per our database at Business Quant, Biogen's Net Income towards Common Stockholders crashed by 12874.51% in 2021 and then skyrocketed by 94836.8% in 2022.
  • Over the past 5 years, Biogen's Net Income towards Common Stockholders (Quarter) stood at -$101.7 million in 2021, then soared by 649.66% to $559.0 million in 2022, then crashed by 55.47% to $248.9 million in 2023, then grew by 7.15% to $266.7 million in 2024, then tumbled by 118.34% to -$48.9 million in 2025.
  • Its last three reported values are -$48.9 million in Q4 2025, $466.5 million for Q3 2025, and $634.8 million during Q2 2025.